Table 2. Relationship between MMR status and clinicopathological characteristics.
| Host characteristics | All n=228 (%) | MMR competent n=193 (%) | dMMR n=35 (%) | P-value |
|---|---|---|---|---|
|
Age (years) | ||||
| <65 | 83 (36) | 71 (37) | 12 (34) | 0.707 |
| 65–74 | 73 (32) | 62 (32) | 11 (32) | |
| >75 | 72 (32) | 60 (31) | 12 (34) | |
|
Sex | ||||
| Male | 108 (47) | 92 (48) | 16 (46) | 0.832 |
| Female | 120 (53) | 101 (52) | 19 (54) | |
|
Diagnosis year | ||||
| 1997–2002 | 142 (62) | 123 (64) | 19 (54) | 0.290 |
| 2003–2007 | 86 (38) | 70 (36) | 16 (46) | |
|
Adjuvant therapy | ||||
| No | 162 (71) | 135 (70) | 27 (77) | 0.389 |
| Yes | 66 (29) | 58 (30) | 8 (23) | |
|
Tumour characteristics | ||||
| Tumour site | ||||
| Colon | 151 (66) | 122 (63) | 29 (83) | 0.024 |
| Rectum | 77 (34) | 71 (37) | 6 (17) | |
| TNM stage | ||||
| I | 25 (11) | 21 (11) | 4 (11) | 0.037 |
| II | 141 (62) | 124 (64) | 17 (49) | |
| III | 62 (27) | 48 (25) | 14 (40) | |
| T stage | ||||
| 1–2 | 127 (55) | 105 (54) | 22 (63) | 0.160 |
| 3 | 77 (34) | 65 (34) | 12 (34) | |
| 4 | 24 (11) | 23 (12) | 1 (3) | |
| N stage | ||||
| 0 | 16 (7) | 14 (7) | 2 (6) | 0.539 |
| 1 | 111 (49) | 91 (47) | 20 (57) | |
| 2 | 101 (44) | 88 (46) | 13 (37) | |
| Differentiation | ||||
| Moderate/well | 200 (88) | 173 (90) | 27 (77) | 0.039 |
| Poor | 28 (12) | 20 (10) | 8 (23) | |
| Venous invasion | ||||
| Absent | 148 (65) | 123 (64) | 25 (71) | 0.381 |
| Present | 80 (35) | 70 (36) | 10 (29) | |
| Margin involvement | ||||
| Absent | 215 (94) | 182 (94) | 33 (94) | 0.997 |
| Present | 13 (6) | 11 (6) | 2 (6) | |
| Peritoneal involvement | ||||
| Absent | 165 (72) | 145 (75) | 20 (57) | 0.029 |
| Present | 63 (28) | 48 (25) | 15 (43) | |
| Tumour perforation | ||||
| Absent | 223 (98) | 188 (97) | 35 (100) | 0.337 |
| Present | 5 (2) | 5 (3) | 0 (0) | |
Abbreviations: CRC=colorectal cancer; dMMR=mismatch repair deficient; MMR=mismatch repair; TNM, tumour, node, metastasis.
The relationship between MMR status and clinicopathological characteristics of patients undergoing elective, potentially curative resection of stage I–III CRC.